Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income remains negative
Q3 FY2026 net income was -$49.97M, compared with -$30.28M a year earlier. Trailing-twelve-month net income was -$152.57M.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$98.71M (+6.4%) for the fiscal year ending Dec 2026, a step up from the -25.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$49.97M-21.3% QoQ
- Last fiscal yearDec 2025
- -$105.43M-25.9% YoY
- LTMSep 2026
- -$152.57M-39.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -65.0% | -2.4% | +62.6 pp |
| 1 year | -25.9% | +6.4% | +32.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (105.43M) USD
- Year-over-year change
- -25.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (105.43M) | -25.9% |
| FY2024 | 2024-12-31 | (83.72M) | -1468.2% |
| FY2023 | 2023-12-31 | (5.34M) | +46.2% |
| FY2022 | 2022-12-31 | (9.93M) | +48.6% |
| FY2021 | 2021-12-31 | (19.32M) | — |
Net Income vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 net income of -$152.57M is the 7th highest of the 10 companies compared; the peer median is -$69.66M.
- Its year-over-year change of -39.7% is the 6th highest of 10, against a peer median of -31.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$26.79M | +81.0% | — | 11.5% | |
| LTM Jun 2026 | -$29.91M | +73.9% | — | 1570.9% | |
| FY2025 | -$55.48M | -255.0% | — | 86687.5% | |
| FY2025 | -$60.63M | -52.3% | — | 4490.9% | |
| LTM Mar 2026 | -$69.66M | +46.5% | — | 832.6% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.43M | -31.1% | — | — |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$152.57M | -39.7% | — | — |
| LTM Jun 2026 | -$163.33M | +8.8% | — | 155.6% | |
| LTM Mar 2026 | -$257.08M | -77.0% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$438.96M | -92.9% | — | 5933.5% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | -$69.66M | -31.1% | — | 1570.9% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 91K | 114K | 111K | 27K | 83K |
| Gross Profit | (91K) | (114K) | (111K) | (27K) | (83K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.83M | 4.46M | 1.01M | 75.06M | 100.64M |
| Selling, General & Admin | 5.41M | 5.26M | 6.17M | 13.04M | 21.33M |
| Operating Expenses | 19.24M | 9.73M | 7.19M | 88.1M | 121.97M |
| Depreciation & Amortization | 91K | 114K | 111K | 27K | 83K |
| EBITDA | (19.23M) | (9.81M) | (5.23M) | (82.23M) | (105.35M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.34M) | (9.84M) | (7.3M) | (88.12M) | (122.05M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 675K | 1.96M | 5.86M | 16.63M |
| Interest Expense | 0 | 0 | 0 | 1.47M | 0 |
| Other Income / Expenses | 13K | (85K) | 1.96M | 4.4M | 16.62M |
| Income Before Tax | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| EPS (Diluted) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| Weighted Avg Shares | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
| Weighted Avg Shares (Diluted) | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.